Dasatinib plus quercetin prevents uterine age-related dysfunction and fibrosis in mice.

The uterine fibrosis contributes to gestational outcomes. Collagen deposition in the uterus is related to uterine aging. Senolytic therapies are an option for reducing health complications related to aging. We investigated effects of aging and the senolytic drug combination of dasatinib plus quercetin (D+Q) on uterine fibrosis. Forty mice, 20 young females (03-months) and 20 old females (18-months), were analyzed. Young (Y) and old (O) animals were divided into groups of 10 mice, with one treatment (T) group (YT and OT) and another control © group (YC and OC). Comparative analysis of and p53 gene expression and related microRNAs (miR34a, miR34b, miR34c, miR146a, miR449a, miR21a, miR126a, and miR181b) among groups was performed to test effects of age and treatment on collagen deposition pathways. Aging promoted downregulation of the signaling pathway ( = 0.005, = 0.031, and = 0.028, respectively) as well as a reduction in expression of miR34c ( = 0.029), miR126a ( = 0.009), and miR181b ( = 0.007). D+Q treatment increased p53 gene expression ( = 0.041) and decreased miR34a ( = 0.016). Our results demonstrate a role for the signaling pathway in uterine aging and suggest for the first time a possible anti-fibrotic effect in the uterus of D+Q senolytic therapy.